Filters
Nanostructured polymeric tools for the treatment and diagnosis of plant diseases and applications in field crops
Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review
Commonly used clinical strategies against coronavirus disease 19 (COVID-19), including the potential role of monoclonal antibodies for site-specific targeted drug delivery, are discussed here. Solid lipid nanoparticles (SLN) tailored with tocilizumab (TCZ) and loading cannabidiol (CBD) are proposed for the treatment of COVID-19 by oral route. TCZ, as a humanized IgG1 monoclonal antibody and an interleukin-6 (IL-6) receptor agonist, can attenuate cytokine storm in patients infected with SARS-CoV-2. CBD (an anti-inflammatory cannabinoid and TCZ agonist) alleviates anxiety, schizophrenia, and depression. CBD, obtained from Cannabis sativa L., is known to modulate gene expression and inflammation and also shows anti-cancer and anti-inflammatory properties. It has also been recognized to modulate angiotensin-converting enzyme II (ACE2) expression in SARS-CoV-2 target tissues. It has already been proven that immunosuppressive drugs targeting the IL-6 receptor may ameliorate lethal inflammatory responses in COVID-19 patients. TCZ, as an immunosuppressive drug, is mainly used to treat rheumatoid arthritis, although several attempts have been made to use it in the active hyperinflammatory phase of COVID-19, with promising outcomes. TCZ is currently administered intravenously. It this review, we discuss the potential advances on the use of SLN for oral administration of TCZ-tailored CBD-loaded SLN, as an innovative platform for managing SARS-CoV-2 and related infections.
Simple Extraction of Cannabinoids from Female Inflorescences of Hemp (Cannabis sativa L.)
The high interest in non-psychoactive cannabidiol increases the need for efficient and straightforward cannabidiol (CBD) extraction methods. The research aimed to compare simple methods of cannabinoid extraction that do not require advanced laboratory equipment. This work assesses the content of total CBD and Δ9-tetrahydrocannabinol (Δ9-THC) in popular solvents such as water and ethanol extracts. Hemp raw material was analyzed with Gas Chromatography with a Flame Ionization Detector (GC-FID), while extracts were tested by High-Performance Liquid Chromatography (HPLC). The female inflorescences of three varieties of industrial hemp were tested: Futura 75, KC Dora, and Tygra (different sowing and N fertilization densities). Tygra (T/10/30) showed the highest content of CBD (0.064%) in water extracts. However, in 80% tincture from Futura 75 (F/30/30), a higher CBD content of 1.393% was observed. The use of 96% ethanol for extraction and ultrasound enabled the highest CBD content to be obtained: 2.682% in Futura 75 (F/30/30). Cold water extraction showed no effect on Δ9-THC content, while hot water extraction increased content from 0.001% in KC Dora to 0.002% in Futura 75 (F/30/30) and Tygra, but the changes were statistically insignificant. Application of 80% ethanol revealed the significantly highest content of Δ9-THC in KC Dora, from 0.026% (K/30/90) to 0.057% (K/30/30), as well as in Tygra (T/30/30) (0.036%) and Futura 75 (F/30/30) (0.048%). The use of ethanol extraction in combination with ultrasound could be an efficient method of obtaining cannabinoids.
Ticks: Biology, Habitat, Threats and Protection Methods
The most common species of tick in Europe is the castor bean tick (Ixodes ricinus), which is found in forests, parks, and gardens and is active almost all year round. Ticks are among the most important arthropods and vectors of disease, transmitting a wide range of parasites that sometimes lead to the death of infected organisms. The peak incidence of tick-borne diseases occurs between May and September; however, due to global warming, people are increasingly exposed to tick-borne diseases throughout the year. In order to increase the possibility of preventing the transmission of diseases by ticks, it is necessary to become thoroughly familiar with the life cycle of ticks and the environment in which they live. Vaccines are available for some diseases, such as tick-borne encephalitis, while others require a highly specific diagnosis. Another major problem is the long period between the tick bite, which often goes unnoticed or is even ignored by the patient or the doctor, and the development of tick-borne diseases. Increasing attention is being paid to the prevention of tick-borne diseases through prevention of tick bites, quick tick removal, use of repellents, appropriate land management, vaccinations, and the use of plants as natural acaricides.
THC-Reduced Cannabis sativa L.—How Does the Solvent Determine the Bioavailability of Cannabinoids Given Orally?
The bioavailability levels of cannabidiol (CBD) and tetrahydrocannabinol (THC) determine their pharmacological effects. Therefore, for medical purposes, it is essential to obtain extracts containing the lowest possible content of the psychogenic component THC. In our extract, the CBD/THC ratio was 16:1, which is a high level compared to available medical preparations, where it is, on average, 1:1. This study assessed the bioavailability and stability of CBD and THC derived from Cannabis sativa L. with reduced THC content. The extract was orally administered (30 mg/kg) in two solvents, Rapae oleum and Cremophor, to forty-eight Wistar rats. The whole-blood and brain concentrations of CBD and THC were measured using liquid chromatography coupled with mass spectrometry detection. Much higher concentrations of CBD than THC were observed for both solvents in the whole-blood and brain after oral administration of the Cannabis sativa extract with a decreased THC content. The total bioavailability of both CBD and THC was higher for Rapae oleum compared to Cremophor. Some of the CBD was converted into THC in the body, which should be considered when using Cannabis sativa for medical purposes. The THC-reduced hemp extract in this study is a promising candidate for medical applications.
Rocznica odkrycia struktury DNA - nowe wyzwania dla medycyny
Odkrycie DNA i poznanie jego struktury miało duże znaczenie zarówno na polu naukowym jak i w życiu codziennym. Rozpoznanie DNA jako związku stanowiącego nośnik informacji genetycznej pozwoliło na rozwój genetyki oraz opracowanie metod genetyki molekularnej. Znalazły one zastosowanie m. in. w medycynie, genetyce sądowej i kryminalistyce, diagnostyce molekularnej chorób genetycznych, pozyskiwaniu substancji bioaktywnych z zastosowaniem biotechnologii roślin, analizie archiwalnego DNA (aDNA), innowacyjnej technologii wykorzystania tkanek transgenicznych zwierząt dla celów biomedycznych, transgenicznych zwierzętach jako bioreaktorach oraz zastosowania organizmów modyfikowanych do prewencji chorób. W kwestii zdrowia, analizy DNA pozwoliły na wykrycie podłoża chorób genetycznych, a także przyczyniły się do poznania mechanizmów prowadzących do ich rozwoju. Techniki genetyki molekularnej znacząco ułatwiają i czynią bardziej dokładnym analizy pokrewieństwa i ocenę przynależności śladów biologicznych pozostawionych na miejscu zbrodni. Stale polepszający się warsztat metod analiz DNA umożliwił też postawienie kolejnego kroku milowego w nauce w postaci opracowania technik sekwencjonowania i poznania genomów człowieka oraz wielu innych organizmów. Z kolei opanowanie informacji genomowej dało możliwość produkcji wielu substancji biologicznie aktywnych na skalę przemysłową.